Filing Details

Accession Number:
0001179110-10-011454
Form Type:
4
Zero Holdings:
No
Publication Time:
2010-07-07 13:00:00
Reporting Period:
2010-07-01
Filing Date:
2010-07-07
Accepted Time:
2010-07-07 09:26:24
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1222244 Prourocare Medical Inc. PUMD Surgical & Medical Instruments & Apparatus (3841) 201212923
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1364107 E Scott Smith 10513 Rigby Dr.
Eden Prairie MN 55437
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock, $0.00001 Par Value Acquisiton 2010-07-01 5,000 $1.60 131,592 No 4 P Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Direct
Reported Derivative Holdings
Sec. Name Sec. Type Price Date Expiration Date Amount Remaning Holdings Nature of Ownership
Common Stock, $0.00001 Par Value Stock Options $7.00 2013-05-30 3,000 3,000 Direct
Common Stock, $0.00001 Par Value Warrants $0.70 2012-12-31 7,000 7,000 Direct
Common Stock, $0.00001 Par Value Stock Options $1.00 2015-08-12 1,000 1,000 Direct
Common Stock, $0.00001 Par Value Stock Options $0.85 2016-03-03 20,000 20,000 Direct
Common Stock, $0.00001 Par Value Stock Options $1.25 2016-08-11 1,000 1,000 Direct
Common Stock, $0.00001 Par Value Stock options $1.50 2016-09-29 30,000 30,000 Direct
Common Stock, $0.00001 Par Value Warrants $1.30 2014-01-07 20,000 42,475 Direct
Common Stock, $0.00001 Par Value Warrants $1.30 2009-11-12 2012-11-12 20,000 20,000 Direct
Expiration Date Amount Remaning Holdings Nature of Ownership
2013-05-30 3,000 3,000 Direct
2012-12-31 7,000 7,000 Direct
2015-08-12 1,000 1,000 Direct
2016-03-03 20,000 20,000 Direct
2016-08-11 1,000 1,000 Direct
2016-09-29 30,000 30,000 Direct
2014-01-07 20,000 42,475 Direct
2012-11-12 20,000 20,000 Direct
Footnotes
  1. Currently exercisable.
  2. Options shall vest on the latter of the date that the Company is cleared by the FDA to sell the ProUroScan System in the United States or the date the Company closes on an aggregate of $2,000,000 or more of incremental equity financing after the date of grant(including the exercise of existing warrants).
  3. Issued to reporting person in lieu of cash for director's fees.